Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between; encouraging industry …
Read More